Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 13, Issue 3, Pages 179-196Publisher
NATURE PORTFOLIO
DOI: 10.1038/nrd4201
Keywords
-
Funding
- German Research Foundation (DFG)
- German Cancer Aid
- German Jose Carreras Leukemia Foundation
- Wilhelm Sander foundation
- European Union [GANNET53]
Ask authors/readers for more resources
Traditional anticancer chemotherapeutics targeting DNA replication and cell division have severe side effects, but they have proved to be highly successful in treating some cancers. Drugs targeting signalling oncoproteins that have gained tumour-driving functions through mutations or overexpression were subsequently developed to increase specificity and thus reduce side effects, but have limitations such as the development of resistance. Now, a new wave of small-molecule anticancer agents is emerging, targeting complex multicomponent cellular machineries - including chromatin modifiers, heat shock protein chaperones and the proteasome - which thus interfere with those support systems that are more essential for cancer cells than for normal cells. Here, we provide our perspective on the advantages and limitations of agents that target tumour-supportive cellular machineries (other than those involving DNA replication), comparing them with agents that target signalling intermediates.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available